Genetics and precision genomics approaches to pulmonary hypertension
European Respiratory Journal · 2024-10 · 64 (4) · 2401370
DOI: 10.1183/13993003.01370-2024 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Respiratory Journal, online erschienen am 29.08.2024. Verfasst von Eric D Austin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt University Medical Center, Nashville, TN, USA richard.trembath@kcl.ac.uk. Hauptthemen laut MEDLINE: Genomics, Hypertension, Pulmonary, Genetic Testing. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: FDA HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Considerable progress has been made in the genomics of pulmonary arterial hypertension (PAH) since the 6th World Symposium on Pulmonary Hypertension, with the identification of rare variants in several novel genes, as well as common variants that confer a modest increase in PAH risk. Gene and variant curation by an expert panel now provides a robust framework for knowing which genes to test and how to interpret variants in clinical practice. We recommend that genetic testing be offered to specific subgroups of symptomatic patients with PAH, and to children with certain types of group 3 pulmonary hypertension (PH). Testing of asymptomatic family members and the use of genetics in reproductive decision-making require the involvement of genetics experts. Large cohorts of PAH patients with biospecimens now exist and extension to non-group 1 PH has begun. However, these cohorts are largely of European origin; greater diversity will be essential to characterise the full extent of genomic variation contributing to PH risk and treatment responses. Other types of omics data are also being incorporated. Furthermore, to advance gene- and pathway-specific care and targeted therapies, gene-specific registries will be essential to support patients and their families and to lay the foundation for genetically informed clinical trials. This will require international outreach and collaboration between patients/families, clinicians and researchers. Ultimately, harmonisation of patient-derived biospecimens, clinical and omic information, and analytic approaches will advance the field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Vanderbilt University Medical Center, Nashville, TN, USA richard.trembath@kcl.ac.uk.
- Indiana University School of Medicine, Indianapolis, IN, USA.
- University of California San Diego, San Diego, CA, USA.
- Department of Medicine, University of Cambridge, Victor Phillip Dahdaleh Heart and Lung Research Institute, Cambridge, UK.
- Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
ORCID-Profile: Eric D Austin, Mona Alotaibi, Stefan Gräf, Wendy K Chung
Förderung
- FDA HHS
- NHLBI NIH HHS
Zitieren
APA
Austin, E. D., Aldred, M. A., Alotaibi, M., Gräf, S., Nichols, W. C., Trembath, R. C., & Chung, W. K. (2024). Genetics and precision genomics approaches to pulmonary hypertension. European Respiratory Journal, 64(4), 2401370. https://doi.org/10.1183/13993003.01370-2024
Vancouver
Austin ED, Aldred MA, Alotaibi M, Gräf S, Nichols WC, Trembath RC, et al. Genetics and precision genomics approaches to pulmonary hypertension. European Respiratory Journal. 2024;64(4):2401370. doi:10.1183/13993003.01370-2024
BibTeX
@article{Austin2024,
author = {Austin, Eric D and Aldred, Micheala A and Alotaibi, Mona and Gräf, Stefan and Nichols, William C and Trembath, Richard C and Chung, Wendy K},
title = {Genetics and precision genomics approaches to pulmonary hypertension},
journal = {European Respiratory Journal},
year = {2024},
volume = {64},
number = {4},
pages = {2401370},
doi = {10.1183/13993003.01370-2024}
}
EUVIMED